Subcutaneous · GLP-1 agonist
Lixisenatide
79 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
79
Ongoing
9
Recruiting
1
Completed
57
Sites
2,091
Countries
63
Endpoints
906
Composite endpoints
82
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
6
Phase 1/2
1
Phase 2
7
Phase 3
33
Phase 4
22
Not applicable
10
Trials by status
Not yet recruiting
3
By invitation
2
Recruiting
1
Active, not recruiting
3
Completed
57
Terminated
6
Unknown
7
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
498
Safety / tolerability / PK
143
Weight & body composition
89
Other (unclassified)
46
Cardiometabolic biomarkers
34
Cardiovascular outcomes
25
Other clinical outcomes
22
Patient-reported / QoL
20
Renal / kidney
15
MASH / liver
10
Heart failure
4
Top 20 metrics across this asset's endpoints
Postprandial glucoseGlycemic
81
HbA1c <7.0% achievementGlycemic
76
HbA1c, changeGlycemic
63
Body weight, absolute change (kg)Weight
53
Fasting glucose, changeGlycemic
50
Documented hypoglycemiaSafety/PK
44
Treatment-emergent AEs (any)Safety/PK
25
HbA1c <6.5% achievementGlycemic
18
C-peptide AUCGlycemic
16
CGM time-in-rangeGlycemic
15
≥5% weight-loss respondersWeight
11
CGM time-above-rangeGlycemic
8
Immunogenicity (ADA)Safety/PK
8
Severe hypoglycemiaSafety/PK
6
Waist circumference, changeWeight
6
Heart rate, changeBiomarker
5
AUC₀-∞Safety/PK
4
Total fat massWeight
4
BMI, changeWeight
3
eGFR, changeRenal
3
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
79 of 79
Showing 1-25 of 79 trials